MedTrace Logo

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

NCT05893537 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-04-16

No results posted yet for this study

Summary

This is a Phase 2, prospective, multicenter, randomized, double-masked, placebo-controlled 104-week study to assess the efficacy, safety, and tolerability of orally delivered CT1812 compared to placebo in participants with GA associated with dry AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Active Comparator CT1812

123 participants will receive a single daily dose of CT1812 (200 mg)

DRUG

Placebo Comparator

123 participants will receive a single daily dose of placebo

Sponsors & Collaborators

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Anthony Caggiano · Cognition Therapeutics Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-16
Primary Completion
2025-03-04
Completion
2025-03-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05893537 on ClinicalTrials.gov